PS3 - Artificial Intelligence in Endocrine Science and Therapeutics

Saturday, November 29, 2025

08:00 - 09:00 Toronto

Location: Constitution Hall

Speaker(s)

Muhammad Mamdani, PharmD, MA, MPH (he/him/his)

Vice President
Unity Health Toronto
University of Toronto
Toronto, Ontario, Canada

Disclosure(s): Baxter: Advisory Board (Terminated, December 30, 2024), Speaker/Honoraria (Terminated, December 30, 2024); Mutuo Health: Advisory Board (Ongoing); Roche: Grant/Research Support (Terminated, February 29, 2024); Signal 1: Advisory Board (Ongoing); Takeda: Advisory Board (Terminated, December 30, 2024), Speaker/Honoraria (Terminated, December 30, 2024)

Moderator(s)

BP

Breay Paty, MD, FRCPC, Chair, CSEM Stream (he/him/his)

Endocrinologist
Vancouver General Hospital
University of British Columbia
Vancouver, British Columbia, Canada

Disclosure(s): Vertex: Grant/Research Support (Ongoing)

Disclosure(s):

Muhammad Mamdani, PharmD, MA, MPH: Baxter: Advisory Board (Terminated, December 30, 2024), Speaker/Honoraria (Terminated, December 30, 2024); Mutuo Health: Advisory Board (Ongoing); Roche: Grant/Research Support (Terminated, February 29, 2024); Signal 1: Advisory Board (Ongoing); Takeda: Advisory Board (Terminated, December 30, 2024), Speaker/Honoraria (Terminated, December 30, 2024)

Breay Paty, MD, FRCPC: Vertex: Grant/Research Support (Ongoing)

Learning Objectives: This session will:
1. Describe the use of artificial intelligence (AI) and machine learning (ML) applications in endocrine and metabolic research, such as high-dimensional data analysis, biomarker discovery, and phenotypic classification.
2. Explore how AI-based tools can accelerate hypothesis generation, drug discovery, and mechanistic understanding of endocrine diseases, and highlight challenges in cross-disciplinary integration and regulatory pathways for innovation.